ANTX

AN2 Therapeutics, Inc.

3.10 USD
+0.01 (+0.32%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AN2 Therapeutics, Inc. stock is down -84.41% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 1 February’s closed higher than January. 0% of analysts rate it a buy.

About AN2 Therapeutics, Inc.

AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

  • Leerink Partners
    Tue Feb 13, 07:38
    hold
    downgrade
  • Evercore Partners
    Mon Feb 12, 12:51
    hold
    downgrade
  • Oppenheimer
    Mon Feb 12, 11:53
    hold
    downgrade
  • JP Morgan
    Mon Feb 12, 11:50
    hold
    downgrade